Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

July 28, 2026 7:00 AM

Altimmune, Inc. (Nasdaq: ALT) announced topline results from its RECLAIM Phase 2 trial evaluating pemvidutide 2.4 mg in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found